Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| RCAX | Tidal Trust II - Defiance Daily Target 2x Long Rcat ETF | $17.35 | $4.18 | 31.77% | 430.2K | - | $11.66$22.31 |
| RLYB | Rallybio | $9.88 | $2.34 | 30.97% | 2.6M | $40M | $1.76$10.70 |
| DFNS | Nukkleus | $2.29 | $0.53 | 30.11% | 4.9M | $51M | $1.76$26.21 |
| ALMU | Aeluma | $19.77 | $4.30 | 27.80% | 38.4K | $279M | $5.79$25.88 |
| USGO | U.s. GoldMining | $15.19 | $3.14 | 26.07% | 15.2K | $160M | $7.42$17.98 |
| CRCG | Themes ETF Trust - Leverage Shares 2x Long Crcl Daily ETF | $3.03 | $0.63 | 26.04% | 27M | - | $0.95$20.92 |
| MGN | Megan | $2.47 | $0.47 | 23.50% | 145.2K | $33M | $1.00$8.63 |
| AAOI | Applied Optoelectronics | $102.36 | $18.13 | 21.52% | 805.3K | $5.8B | $9.71$110.00 |
| PURR | Hyperliquid Strategies | $4.95 | $0.87 | 21.35% | 5.1M | $506M | $3.01$5.78 |
| EMAT | Evolution Metals & Technologies | $9.67 | $1.70 | 21.33% | 4.2K | $23M | $5.50$24.37 |
| CGEN | Compugen | $2.20 | $0.39 | 21.27% | 20.5K | $169M | $1.13$2.38 |
| ASTH | Astrana Health | $24.46 | $4.13 | 20.32% | 46.5K | $1.0B | $18.08$34.80 |
| OCUL | Ocular Therapeutix | $10.71 | $1.77 | 19.80% | 258.5K | $1.9B | $5.79$16.44 |
| SOLT | Volatility Shares Trust - 2x Solana ETF | $55.29 | $9.06 | 19.60% | 423.6K | - | $41.00$706.00 |
| VG | Venture Global | $11.56 | $1.87 | 19.30% | 898.1K | $24B | $5.72$19.50 |
| SYPR | Sypris Solutions | $3.48 | $0.52 | 17.57% | 137.5K | $68M | $1.42$4.74 |
| MVO | Mv Oil Trust | $2.41 | $0.34 | 16.46% | 1.3M | $24M | $0.97$6.60 |
| CHNR | China Natural Resources | $3.76 | $0.53 | 16.25% | 131.2K | $4.0M | $3.16$8.20 |
| MRAL | GraniteShares ETF Trust - GraniteShares 2x Long Mara Daily ETF | $4.31 | $0.60 | 16.17% | 1.2M | - | $2.21$36.63 |
| RCAT | Red Cat | $13.53 | $1.88 | 16.16% | 21.5M | $1.4B | $4.58$18.02 |
Related Articles
Featured Article
Why Venture Global Fell Back to Its April Lows in November
Billy Duberstein|Dec 8, 2025
Venture Global lowered full-year guidance as its legal troubles mount.
Wall Street Thinks These 2 Biotech Stocks Could Soar in 2024
George Budwell, PhD|Jan 3, 2024
These two biotech stocks sport notable 12-month price targets. However, they are also uber-risky.
This Exciting Biopharma Could Earn You 55% in 12 Months
Jeffrey Little|Aug 22, 2021
When patients see more clearly, so too should investors.
4 Reasons I Just Bought Ocular Therapeutix Stock
Cory Renauer|Aug 21, 2021
This company's drug delivery technology just isn't getting the appreciation it deserves right now.
Can Ocular Therapeutix Reach Its Full Potential?
Brian Orelli, PhD and Keith Speights|Apr 1, 2021
The biotech has a ways to go.
![Can_Ocular_Therapeutix_Reach_Its_Full_Potential[1]](https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F619459%2Fcan_ocular_therapeutix_reach_its_full_potential1.jpg&w=384&op=resize)
3 Top Healthcare Stocks to Buy Now
Cory Renauer|Feb 17, 2021
Find out how shares of these disruptive businesses could make you rich.
3 Reasons to Buy Ocular Therapeutix Stock Right Now
Cory Renauer|Feb 16, 2021
There are a few reasons this could be the best biotech stock you can buy at the moment.
3 Top 5G Stocks to Buy in September
5G networks have made nationwide debuts, but these hardware stocks could have the most to gain.
2 Top Biotech Picks for May
Zhiyuan Sun|May 20, 2020
Here are the hottest companies coming up in the biotech sector.
Can This Biotech Shed New Light on Cancer Immunotherapies?
Zhiyuan Sun|May 4, 2020
Its new discovery in the field of cancer immunotherapy produced mixed clinical results, but it certainly has ample backing from the big players.
